Send us Feedback

Eli Lilly and Company (LLY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

LLY » Topics » Patent Licenses

This excerpt taken from the LLY 10-K filed Feb 22, 2010.
Patent Licenses
Most of our important products were discovered in our own laboratories and are not subject to significant license agreements. Two of our larger products, Cialis and Alimta, are subject to patent assignments or licenses granted to us by others.
 
  •  The compound patent for Cialis is the subject of a license agreement with Glaxo SmithKline which assigns to us exclusively all rights in the compound. The agreement calls for royalties of a single-digit percentage of net sales. The agreement is not subject to termination by Glaxo for any reason other than a material breach by Lilly of the royalty obligation, after a substantial cure period.
 
  •  The compound patent for Alimta is the subject of a license agreement with Princeton University, granting us an irrevocable exclusive worldwide license to the compound patents for the lives of the patents in the respective territories. The agreement calls for royalties of a single-digit percentage of net sales. The agreement is not subject to termination by Princeton for any reason other than a material breach by Lilly of the royalty obligation, after a substantial cure period. Alimta is also the subject of a worldwide, nonexclusive license to certain compound and process patents owned by Takeda Pharmaceutical Company Limited. The agreement calls for royalties of a single-digit percentage of net sales in countries covered by a relevant patent. The agreement is subject to termination for material default and failure to cure by Lilly and in the event that Lilly becomes bankrupt or insolvent.
 
These excerpts taken from the LLY 10-K filed Feb 27, 2009.
Patent Licenses
 
Most of our important products were discovered in our own laboratories and are not subject to significant license agreements. Two of our larger products, Cialis and Alimta, are subject to patent assignments or licenses granted to us by others.
 
•   The compound patent for Cialis is the subject of a license agreement with Glaxo SmithKline which assigns to us exclusively all rights in the compound. The agreement calls for royalties of a single-digit percentage


-5-

 

of net sales. The agreement is not subject to termination by Glaxo for any reason other than a material breach by Lilly of the royalty obligation, after a substantial cure period.
 
•   The compound patent for Alimta is the subject of a license agreement with Princeton University, granting us an irrevocable exclusive worldwide license to the compound patents for the lives of the patents in the respective territories. The agreement calls for royalties of a single-digit percentage of net sales. The agreement is not subject to termination by Princeton for any reason other than a material breach by Lilly of the royalty obligation, after a substantial cure period. Alimta is also the subject of a worldwide, nonexclusive license to certain compound and process patents owned by Takeda Pharmaceutical Company Limited. The agreement calls for royalties of a single-digit percentage of net sales in countries covered by a relevant patent. The agreement is subject to termination for material default and failure to cure by Lilly and in the event that Lilly becomes bankrupt or insolvent.
 
Patent
Licenses


 



Most of our important products were discovered in our own
laboratories and are not subject to significant license
agreements. Two of our larger products, Cialis and Alimta, are
subject to patent assignments or licenses granted to us by
others.


 














•  
The compound patent for Cialis is the subject of a license
agreement with Glaxo SmithKline which assigns to us exclusively
all rights in the compound. The agreement calls for royalties of
a single-digit percentage





-5-




 


















of net sales. The agreement is not subject to termination by
Glaxo for any reason other than a material breach by Lilly of
the royalty obligation, after a substantial cure period.


 














•  
The compound patent for Alimta is the subject of a license
agreement with Princeton University, granting us an irrevocable
exclusive worldwide license to the compound patents for the
lives of the patents in the respective territories. The
agreement calls for royalties of a single-digit percentage of
net sales. The agreement is not subject to termination by
Princeton for any reason other than a material breach by Lilly
of the royalty obligation, after a substantial cure period.
Alimta is also the subject of a worldwide, nonexclusive license
to certain compound and process patents owned by Takeda
Pharmaceutical Company Limited. The agreement calls for
royalties of a single-digit percentage of net sales in countries
covered by a relevant patent. The agreement is subject to
termination for material default and failure to cure by Lilly
and in the event that Lilly becomes bankrupt or insolvent.


 




EXCERPTS ON THIS PAGE:

10-K
Feb 22, 2010
10-K (2 sections)
Feb 27, 2009

RELATED TOPICS for LLY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki